| cpd01532 | 332180-28-6 | partially truncated AP-1-like peptide | AKSRA | Anthraquinone derivative | Anticancer therapy, cell proliferation and malignant transformation inhibition | amide | Ijaz, T.et.al (2001)
DOI |
cpd01533 | 332180-27-5 | partially truncated AP-1-like peptide | AKCRA | Anthraquinone derivative | Anticancer therapy, cell proliferation and malignant transformation inhibition | amide | Ijaz, T.et.al (2001)
DOI | cpd01534 | 332180-26-4 | partially truncated AP-1-like peptide | ARCKA | Anthraquinone derivative | Anticancer therapy, cell proliferation and malignant transformation inhibition | amide | Ijaz, T.et.al (2001)
DOI | cpd01535 | 330808-07-6 | oligoglycin | GGGGG | Camptothecin | Synthesis | amide | Harada, M.et.al (2000)
DOI | cpd01536 | 330808-06-5 | oligoglycin | GGGG | Camptothecin | Synthesis | amide | Harada, M.et.al (2000)
DOI | cpd01537 | 330808-05-4 | oligoglycin | GGG | Camptothecin | Synthesis | amide | Harada, M.et.al (2000)
DOI | cpd01538 | 330808-04-3 | oligoglycin | GG | Camptothecin | Synthesis | amide | Harada, M.et.al (2000)
DOI | cpd01539 | 330808-02-1 | oligoglycin | GGGGG | Camptothecin | Synthesis | amide | Harada, M.et.al (2000)
DOI | cpd01540 | 330808-01-0 | oligoglycin | GGGG | Camptothecin | Synthesis | amide | Harada, M.et.al (2000)
DOI | cpd01541 | 330808-00-9 | oligoglycin | GGG | Camptothecin | Synthesis | amide | Harada, M.et.al (2000)
DOI | cpd01542 | 330807-99-3 | oligoglycin | GG | Camptothecin | Synthesis | amide | Harada, M.et.al (2000)
DOI | cpd01543 | 192991-32-5 | tetrapeptide | GGFG | Camptothecin | Synthesis | amide | Harada, M.et.al (2000)
DOI | cpd01544 | 303956-67-4 | tetrapeptide | CLLL | Irofulven derivative | Anticancer therapy, alkylating agent | sulfide | McMorris, Trevor C.et.al (2000)
DOI | cpd01545 | 303956-66-3 | tetrapeptide | CLLF | Irofulven derivative | Anticancer therapy, alkylating agent | sulfide | McMorris, Trevor C.et.al (2000)
DOI | cpd01546 | 303956-65-2 | tetrapeptide | CLGF | Irofulven derivative | Anticancer therapy, alkylating agent | sulfide | McMorris, Trevor C.et.al (2000)
DOI | cpd01547 | 303956-64-1 | tetrapeptide | CFGL | Irofulven derivative | Anticancer therapy, alkylating agent | sulfide | McMorris, Trevor C.et.al (2000)
DOI | cpd01548 | 278807-01-5 | tripeptide | GAA | 9-(Phenylamino)-4-acridinecarboxylic acid | Synthesis and analytics | amide | Carlson, Coby B.et.al (2000)
DOI | cpd01549 | 278806-99-8 | tripeptide | GKK | 9-(Phenylamino)-4-acridinecarboxylic acid | Synthesis and analytics | amide | Carlson, Coby B.et.al (2000)
DOI | cpd01550 | 278806-98-7 | tripeptide | GRS | 9-(Phenylamino)-4-acridinecarboxylic acid | Synthesis and analytics | amide | Carlson, Coby B.et.al (2000)
DOI | cpd01551 | 273383-48-5 | vasoactive intestinal peptide (VIP) fragment | RKQMAVKKYLN | 3H-Indolium, 5-carboxy-2-[7-[1,3-dihydro-3,3-dimethyl-1-(4-sulfobutyl)-2H-indol-2-ylidene]-1,3,5-heptatrien-1-yl]-3,3-dimethyl-1-(4-sulfobutyl)-, inner salt | Synthesis and analytics | amide | Licha, Kai;et.al (2000)
DOI | cpd01552 | 273383-46-3 | model peptide | LAILA | 3H-Indolium, 5-carboxy-2-[7-[1,3-dihydro-3,3-dimethyl-1-(4-sulfobutyl)-2H-indol-2-ylidene]-1,3,5-heptatrien-1-yl]-3,3-dimethyl-1-(4-sulfobutyl)-, inner salt | Synthesis and analytics | amide | Licha, Kai;et.al (2000)
DOI | cpd01553 | 258824-89-4 | lysosomally degradable peptide | XQGFLGK | Tetraphenyl porphyrin (TPP) derivative | Synthesis, controlled attachment of porphyrins to peptides and other compounds | amide | Matthews, Susan E.et.al (1999)
DOI | cpd01554 | 258824-84-9 | lysosomally degradable peptide | XQGFLG | Tetraphenyl porphyrin (TPP) derivative | Synthesis, controlled attachment of porphyrins to peptides and other compounds | amide | Matthews, Susan E.et.al (1999)
DOI | cpd01555 | 258824-83-8 | lysosomally degradable peptide | XQGFLGK | Tetraphenyl porphyrin (TPP) derivative | Synthesis, controlled attachment of porphyrins to peptides and other compounds | amide | Matthews, Susan E.et.al (1999)
DOI | cpd01556 | 258824-82-7 | lysosomally degradable peptide | XGFLGK | Tetraphenyl porphyrin (TPP) derivative | Synthesis, controlled attachment of porphyrins to peptides and other compounds | amide | Matthews, Susan E.et.al (1999)
DOI | cpd01557 | 258824-81-6 | lysosomally degradable peptide | XKGFLG | Tetraphenyl porphyrin (TPP) derivative | Synthesis, controlled attachment of porphyrins to peptides and other compounds | amide | Matthews, Susan E.et.al (1999)
DOI | cpd01558 | 258824-80-5 | lysosomally degradable peptide | XGFLGK | Tetraphenyl porphyrin (TPP) derivative | Synthesis, controlled attachment of porphyrins to peptides and other compounds | amide | Matthews, Susan E.et.al (1999)
DOI | cpd01559 | 258824-79-2 | lysosomally degradable peptide | XKGFLG | Tetraphenyl porphyrin (TPP) derivative | Synthesis, controlled attachment of porphyrins to peptides and other compounds | amide | Matthews, Susan E.et.al (1999)
DOI | cpd01560 | 171290-87-2 | tripeptide | GQX | Tetraphenyl porphyrin (TPP) derivative | Synthesis, controlled attachment of porphyrins to peptides and other compounds | amide | Matthews, Susan E.et.al (1999)
DOI | cpd01561 | 171290-86-1 | tripeptide | GKX | Tetraphenyl porphyrin (TPP) derivative | Synthesis, controlled attachment of porphyrins to peptides and other compounds | amide | Matthews, Susan E.et.al (1999)
DOI |